tTG-DGP BIOMARKERS FOR MONITORING CELIAC DISEASE
AssigneeVibrant Holdings, LLC
InventorsRok Seon Choung, Eric V. Marietta, Vasanth Jayaraman, Karthik Krishna, Joseph A. Murray
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., Celiac disease. Furthermore, a set of novel biomarkers for Celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.
Claims48
An array comprising an array surface and at least two peptide probes, wherein each of the at least two peptide probes comprises a binding motif selected from the group consisting of SEQ ID NOS:
- 1-172, and wherein the at least two peptide probes extend from the array surface.
An array of features attached to a surface at positionally-defined locations, the features comprising at least one engineered polypeptide chain comprising at least two epitope sequences from a bioactive polypeptide that generates an immune response in subject having Celiac disease and at least one epitope sequence from a protein that binds to antibodies of the subject having Celiac disease.
A method of detecting healing status in a subject having Celiac disease, the method comprising:
- obtaining a sample from the subject, the subject sample in part comprising subject antibodies;
- contacting an array of synthetic polypeptides with the subject sample, each synthetic polypeptide comprising at least two epitope sequences from a bioactive polypeptide that generates an immune response in subjects having Celiac disease and at least one epitope sequence from a protein that binds to the subject antibodies;
- identifying an antibody-binding intensity value for each of the synthetic polypeptides in the array;
- and
- determining a healing status of the subject based on the identified antibody-binding intensity values for each of the synthetic polypeptides in the array.
A method of identifying synthetic polypeptides for detecting healing status in a subject having Celiac disease, the method comprising one or more of the following steps:
- estimating the antibody-binding intensity of an array of synthesized tTG-DGP neoepitopes wherein antibody-binding intensity values are linked to corresponding peptide sequences;
- eliminating background noise using background normalization modeling performed with an expectation-maximization algorithm;
- applying vector machine modeling to a training set of peptides to construct a hyperplane and maximize the margins of the training data between the 2 classes (Celiac disease vs no Celiac disease), wherein a set of disease-associated peptide sequences of the tTG-DGP complex are determined;
- determining the sensitivity and specificity of each peptide identified as a disease-associated peptide sequence of the tTG-DGP complex;
- and
- identifying a further set of immunogenic epitopes of the tTG-DGP complex based on the sensitivity, specificity and predictability of Celiac disease associated with the peptides in the set.
An array for detecting healing status in a subject having Celiac disease, the array comprising one or more of the sequences selected from the group consisting of SEQ ID NOS:
- 1-172.
A substantially purified and/or recombinant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 1-172, or a biologically active fragment or variant of any one or more thereof.
A method of treating Celiac disorder or a Celiac related disorder in a patient, comprising administering to the patient a formulation comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 1-127, or a biologically active fragment or variant of any one or more thereof.
A method for determining the degree of Celiac disorder or a Celiac related disorder in a patient, comprising measuring a reactivity of a serum sample of the patient contacted by a formulation comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 1-172, or a biologically active fragment or variant of any one or more thereof.
A biomarker for Celiac disease comprising a polypeptide epitope for a Celiac antibody, wherein the polypeptide epitope is selected from the group consisting of SEQ ID NOS:
- 1-172, or a biologically active fragment or variant of any one or more thereof.
Dependencies are inferred from the claim text.